End-stage kidney disease Urological and Genital Diseases Kidney disease
Conditions
Interventions
rT-PA 1 mg/lumen as a dialysis catheter locking solution used once per week, compared to heparin 5000 units/ml (luminal volume).
Sponsors
University of Calgary (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. End-stage renal disease (ESRD) patients 18 years of age and older with newly inserted permanent, tunnelled, dual-lumen catheters 2. Naive to study but not naive to catheters 3. Expected to use catheter for at least six months 4. Frequency of dialysis three times per week 5. Baseline international normalised ratio (INR) less than or equal to 1.3 6. Baseline platelet count greater than or equal to 60
Exclusion criteria
Exclusion criteria: 1. Use of systemic anticoagulation 2. Insertion of catheter by guide-wire exchange 3. Insertion of catheter into femoral vein 4. Current use of antibiotics for catheter-related bacteraemia 5. Major haemorrhage within prior 4 weeks 6. History of intra-cranial or intra-spinal neoplasm 7. Allergy to rT-PA 8. Active pericarditis 9. Weight less than 30 kg 10. Pregnant or lactating 11. Major surgery in past 48 hours 12. Presence of fever
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Catheter malfunction. | — |
Secondary
| Measure | Time frame |
|---|---|
| Catheter related bacteremia. | — |
Countries
Canada
Outcome results
None listed